These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15452464

  • 1. Gemifloxacin (factive).
    Med Lett Drugs Ther; 2004 Sep 27; 46(1192):78-9. PubMed ID: 15452464
    [No Abstract] [Full Text] [Related]

  • 2. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS.
    Expert Rev Anti Infect Ther; 2008 Aug 27; 6(4):405-18. PubMed ID: 18662107
    [Abstract] [Full Text] [Related]

  • 3. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B, Schafer KR.
    Expert Rev Anti Infect Ther; 2010 Nov 27; 8(11):1259-71. PubMed ID: 21073291
    [Abstract] [Full Text] [Related]

  • 4. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK, Triller DM, Yong CS, Lodise TP.
    Ann Pharmacother; 2004 Nov 27; 38(7-8):1226-35. PubMed ID: 15187209
    [Abstract] [Full Text] [Related]

  • 5. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM, Tillotson G.
    Int J Antimicrob Agents; 2008 Apr 27; 31(4):299-306. PubMed ID: 18276120
    [Abstract] [Full Text] [Related]

  • 6. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul 27; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 7. [The clinical and pharmacoeconomic aspects of gemifloxacin(corrected) use in the patients with extra-hospital pneumonia in stationary conditions].
    Zaĭtsev AA, Sinopal'nikova AI.
    Voen Med Zh; 2007 Jan 27; 328(1):44-51. PubMed ID: 17436714
    [No Abstract] [Full Text] [Related]

  • 8. Gemifloxacin for community-acquired pneumonia.
    Lode HM, Schmidt-Ionas M, Stahlmann R.
    Expert Opin Investig Drugs; 2008 May 27; 17(5):779-86. PubMed ID: 18447602
    [Abstract] [Full Text] [Related]

  • 9. Fluoroquinolones in the management of community-acquired pneumonia.
    Albertson TE, Dean NC, El Solh AA, Gotfried MH, Kaplan C, Niederman MS.
    Int J Clin Pract; 2010 Feb 27; 64(3):378-88. PubMed ID: 20456176
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2008 Jan 27; 60(1):59-64. PubMed ID: 17889491
    [Abstract] [Full Text] [Related]

  • 11. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
    File TM, Tillotson GS.
    Expert Rev Anti Infect Ther; 2004 Dec 27; 2(6):831-43. PubMed ID: 15566328
    [Abstract] [Full Text] [Related]

  • 12. Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.
    Zhang L, Wang R, Falagas ME, Chen LA, Liu YN.
    Chin Med J (Engl); 2012 Feb 27; 125(4):687-95. PubMed ID: 22490497
    [Abstract] [Full Text] [Related]

  • 13. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity.
    Singh A.
    Clin Infect Dis; 2007 Jul 01; 45(1):133; author reply 134-5. PubMed ID: 17554716
    [No Abstract] [Full Text] [Related]

  • 14. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
    Laterre PF.
    Clin Infect Dis; 2008 May 15; 46(10):1510-2. PubMed ID: 18419483
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
    Hammerschlag MR.
    J Antimicrob Chemother; 2001 Nov 15; 48(5):735. PubMed ID: 11679567
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S, Yanagihara K, Izumikawa K, Seki M, Kakeya H, Yamamoto Y, Senjyu H, Saito A, Kohno S.
    J Infect; 2009 Sep 15; 59(3):222-4. PubMed ID: 19592113
    [No Abstract] [Full Text] [Related]

  • 18. Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness.
    File TM, Tan JS.
    Clin Infect Dis; 2005 Dec 15; 41(12):1706-8. PubMed ID: 16288391
    [No Abstract] [Full Text] [Related]

  • 19. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Moran G.
    J Emerg Med; 2006 May 15; 30(4):377-87. PubMed ID: 16740445
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
    File TM, Schlemmer B, Garau J, Cupo M, Young C, 049 Clinical Study Group.
    J Antimicrob Chemother; 2001 Jul 15; 48(1):67-74. PubMed ID: 11474633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.